| |
![Moving Away from Spreadsheets: How to Know When It’s Time]() MOVING AWAY FROM SPREADSHEETS: HOW TO KNOW WHEN IT’S TIME whitepaper Jul 23, 2018 The spreadsheet conundrum... Joe Smith, sales director for Great Start-Up Number 5 Billion and Thirty-One, puts on a blindfold and reaches out blindly for something, ANYTHING, to help him organize his team’s deals and commissions. He’s ho... Read More |
![Why Enterprise CPQ Implementations Fail]() WHY ENTERPRISE CPQ IMPLEMENTATIONS FAIL whitepaper Jul 23, 2018 You’ve reached a certain point in the evolution of your company and you know it’s time to invest in a CPQ system. But buyer beware: There’s a certain misconception around CPQ systems as being plug-in devices or turnkey-ready overlays of your existing... Read More |
| |
![Incentive Compensation Management: Build Versus Buy]() INCENTIVE COMPENSATION MANAGEMENT: BUILD VERSUS BUY whitepaper Jul 23, 2018 Custom ICM solutions are built for you, not auditors, so they typically don’t offer visibility into actions performed over time. Auditors may lack confidence in your homegrown system, especially if they find errors or omissions. In fact, audit ... Read More |
| |
![Tufts CSDD-Veeva eClinical Study CRO Report]() TUFTS CSDD-VEEVA ECLINICAL STUDY CRO REPORT whitepaper Jul 06, 2018 See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Findings include. Anticipated growth and variety of data sources used by C... Read More |
![Ideas to Make Health Care Affordable Again]() IDEAS TO MAKE HEALTH CARE AFFORDABLE AGAIN whitepaper Jun 29, 2018 More Americans are concerned about health care costs (85%) that are concerned about other common worries like retirement (73%), housing (66%), and child care (49%).1 While Republicans, Democrats, and independents are divided over many healthcare issu... Read More |
![Accelerating the Journey from Research to Clinic]() ACCELERATING THE JOURNEY FROM RESEARCH TO CLINIC whitepaper Jun 26, 2018 Bridging the gap from discovery to verification and validation requires high-performing instruments and software as well as competency in mass spec-based biomarker discovery and method development for biomarker verification. The Thermo Scientific&tra... Read More |
| |
![The Impact of the Clinical Educator]() THE IMPACT OF THE CLINICAL EDUCATOR whitepaper Jun 12, 2018 From passive consumer to active participant, the role of the patient is changing as dramatically as the healthcare system itself. The fee-for-service, volume-based care of the past is giving way to a value-based care system focusing on quality and ou... Read More |
| |
![THE FUTURE OF THE PHARMACEUTICAL INDUSTRY]() THE FUTURE OF THE PHARMACEUTICAL INDUSTRY whitepaper Jun 05, 2018 Ever participated in one of those benchmarking exercises? You know what I mean. When a (usually) fresh-faced consultant asks lots of questions and fills in a spreadsheet comparing what you do with your competitors. Well, beware. Trying to copy and fo... Read More |
![HOW TO EXTEND IDENTITY SECURITY TO YOUR API’S]() HOW TO EXTEND IDENTITY SECURITY TO YOUR API’S whitepaper May 25, 2018 The number of users and devices requesting access to applications is growing exponentially, and enterprises are scrambling to adapt their authentication and authorization infrastructure to deal with this fast growth. REST APIs are a critical new appl... Read More |
![Manufacturing Of Sterile Aqueous Suspensions: A Primer]() MANUFACTURING OF STERILE AQUEOUS SUSPENSIONS: A PRIMER whitepaper May 15, 2018 Manufacturing of sterile aqueous suspensions requires the thorough understanding of the factors that influence their physical and chemical stability. Particle morphology of the active pharmaceutical ingredient (API) plays a key factor in drug product... Read More |
![Avoid Clinical Trial Enrollment Pitfalls]() AVOID CLINICAL TRIAL ENROLLMENT PITFALLS whitepaper May 06, 2018 Selecting the right site is the single most crucial decision
you’ll make about your next clinical trial. And perhaps the
single most important consideration in selecting a site is
whether it can make its enrollment. Many do... Read More |
| |
![Digital Pathology in Accelerating Drug Development]() DIGITAL PATHOLOGY IN ACCELERATING DRUG DEVELOPMENT whitepaper Apr 25, 2018 Tissue pathology is at the core of various aspects of the pharmaceutic pipeline. Digital pathology is a technology that converts glass microscope slides with tissue samples into whole slide digital images, which can be used to identify, quantify, and... Read More |
![ALIGNING STAKEHOLDERS IN A NEW HEALTHCARE ECOSYSTEM]() ALIGNING STAKEHOLDERS IN A NEW HEALTHCARE ECOSYSTEM whitepaper Apr 05, 2018 Preventable chronic diseases such as diabetes, cardiovascular disease, and cancers are responsible for over 40 of the 56 million annual deaths worldwide (7 out of every 10 deaths). Our medical communities spend vast resources battling complications o... Read More |
| |
![The Benefits of Aqueous Critical Cleaning]() THE BENEFITS OF AQUEOUS CRITICAL CLEANING whitepaper Mar 20, 2018 Aqueous cleaners are typically formulated to ensure maximal cleaning performance by using key ingredients such as surface active agents (surfactants) excellent wetting agents that allow the cleaning solution to penetrate into crevices while getting u... Read More |
![AN ANALYSIS OF DRUG THERAPY TAPERING GUIDELINES]() AN ANALYSIS OF DRUG THERAPY TAPERING GUIDELINES whitepaper Mar 16, 2018 Chronic pain, the kind of pain a person wakes up with every morning and goes to sleep with every night, has a standard of care that is often incomplete and sometimes inaccurate. Chronic pain treatment often revolves around drug therapy and managing s... Read More |
![Analysis Using Counter-rotating Twin Screw Extruder]() ANALYSIS USING COUNTER-ROTATING TWIN SCREW EXTRUDER whitepaper Mar 14, 2018 While the co-rotating, intermeshing TSE is more commonly used in pharmaceutical R&D and production, the counter-rotating, intermeshing TSE is a viable tool to successfully process these formulations. Energy input must be strategically balanced to... Read More |
![High capacity containment check screening]() HIGH CAPACITY CONTAINMENT CHECK SCREENING whitepaper Mar 10, 2018 This paper will discuss the aspects of bioburden reduction in a manufacturing area or cleanroom during operational shutdown or for routine maintenance scheduling. Relevant regulatory requirements are overviewed, along with the factors constituting as... Read More |
![A Recent History of Antibiotics and Where We May Be Going]() A RECENT HISTORY OF ANTIBIOTICS AND WHERE WE MAY BE GOING whitepaper Mar 01, 2018 About Clinical Research Management, Inc. Clinical Research Management (ClinicalRM) is not only involved in the testing of new antibiotics in Phase I, II, III studies, monitoring protocol development, site selection, and assistance with FDA approvals,... Read More |
![4 Pillars Pharma Distributors Can Stand On]() 4 PILLARS PHARMA DISTRIBUTORS CAN STAND ON whitepaper Feb 21, 2018 Despite a recent global economic downturn, the world pharmaceutical market is currently estimated to be valued at around $300 billion and rising, according to the World Health Organization (WHO). In a recent post, the WHO states that more than a thir... Read More |
![Using Technology to Revolutionize the Health Care Industry]() USING TECHNOLOGY TO REVOLUTIONIZE THE HEALTH CARE INDUSTRY whitepaper Feb 18, 2018 What if we could focus interventions on the exact group that can be most impacted? Target those that can benefit most from a particular series of actions? Identify transient patients so they could be intensely targeted before they move on? Effectivel... Read More |
![TRACK & TRACE IN THE PHARMACEUTICAL INDUSTRY]() TRACK & TRACE IN THE PHARMACEUTICAL INDUSTRY whitepaper Feb 13, 2018 The pharmaceutical industry is not short of challenges patent cliffs, regulatory scrutiny, and R&D productivity, as well as a complex supply chain. Pharmaceutical products see several changes of hands from the manufacturers to distributors to dis... Read More |
| |
![Pharma R&D Annual Review 2017]() PHARMA R&D ANNUAL REVIEW 2017 whitepaper Jan 12, 2018 Welcome to Pharmaprojects’ 2017 review of trends in pharmaceutical R&D. For around a quarter of a century now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’ll look at how the land li... Read More |
| |
![Medical Research Law & Policy Report]() MEDICAL RESEARCH LAW & POLICY REPORT whitepaper Jan 03, 2018 Will the 21st Century Cures Act further its aim to boost drug and device development in 2018? That's one of the questions the life sciences industry and attorneys are asking for the new year. The law provides extra money for research and developm... Read More |
![Reforming Biopharmaceutical Pricing at Home and Abroad]() REFORMING BIOPHARMACEUTICAL PRICING AT HOME AND ABROAD whitepaper Nov 23, 2017 The affordability of healthcare and biopharmaceutical drugs is a top concern for Americans. It is often asserted that promoting innovation and affordable drugs are conflicting goals. New innovations, however, often provide improved health that was no... Read More |
| |
| |
![Accelerating precision medicine]() ACCELERATING PRECISION MEDICINE whitepaper Oct 17, 2017 The fully realized vision of precision medicine includes the capability to rapidly diagnose, sequence and develop a personalized treatment plan based on combined analysis of genotype, phenotype, environmental, clinical and behavioral data. Precision ... Read More |
![The Scientific Path To Cycle Development]() THE SCIENTIFIC PATH TO CYCLE DEVELOPMENT whitepaper Oct 17, 2017 Management of medication delivery through lyophilization - freeze-drying - is a crucial enabling process technology for many important parenteral drugs. Close to 50% of biopharmaceuticals, including enzymes, proteins and monoclonal antibodies, must b... Read More |
![The National Pharmaceutical Strategy 2016 2018]() THE NATIONAL PHARMACEUTICAL STRATEGY 2016 2018 whitepaper Oct 16, 2017 The Government and the Swedish Association of Local Authorities and Regions, together with a broad set of pharmaceutical actors, have agreed to continue to build on and enhance the work that has been in progress for several years under the National P... Read More |
![Liposome Technology]() LIPOSOME TECHNOLOGY whitepaper Oct 09, 2017 Polymun offers the development of liposomal formulations for all kinds of pharmaceutically active ingredients and vaccine antigens. A broad spectrum of analytical methods has been established for this purpose. Polymun produces GMP material including ... Read More |
![De-Risking Antibiotic Drug Development with PK-PD]() DE-RISKING ANTIBIOTIC DRUG DEVELOPMENT WITH PK-PD whitepaper Oct 05, 2017 Pharmacometrics, which includes the science of pharmacokinetics-pharmacodynamics (PK-PD), is one of the most commonly misunderstood, misused, and under-appreciated resources available to drug developers. In the past PK-PD was an afterthought, but tod... Read More |
![Access controls for medical devices]() ACCESS CONTROLS FOR MEDICAL DEVICES whitepaper Sep 27, 2017 Healthcare information technology has quickly become one of a clinician’s most powerful instruments. The implementation of technology to automate the collection and documentation of patient information, such as vital signs, continues to expand ... Read More |
![The BlockRx pharma Ecosystem]() THE BLOCKRX PHARMA ECOSYSTEM whitepaper Sep 21, 2017 BlockRx is a series of initiatives presented by iSolve, a privately owned Blockchain solution provider for the Life Sciences Industry. The mission of BlockRx is to interconnect systems that do not readily communicate, establish data provenance that s... Read More |
| |
| |
| |
![Value-Based Contracting for Oncology Drugs]() VALUE-BASED CONTRACTING FOR ONCOLOGY DRUGS whitepaper Aug 29, 2017 A revolution is occurring in cancer treatment, based on new insights into the biology of cancer, and resulting in dozens of new drugs on the market or in the development pipeline. Many of these new drugs are “targeted” therapies that are ... Read More |
![Agile Process Development In Biopharmaceuticals]() AGILE PROCESS DEVELOPMENT IN BIOPHARMACEUTICALS whitepaper Aug 23, 2017 The development of novel therapeutic products involves a complex network of internal departments and external partners. Different groups across Process Development organizations typically use a variety of approaches to capture, manage, analyze and re... Read More |
![BREAST CANCER DRUGS FUNDING AND TRIALS]() BREAST CANCER DRUGS FUNDING AND TRIALS whitepaper Aug 01, 2017 This white paper arises out of the Pink Ribbon drugs funding & trials conference, held at the faculty of pharmaceutical medicine on 23 March 2017 (full programme provided on page 13-15). The general theme to emerge from the conference is that the... Read More |
| |
![Sponsor CRO Pharmacovigilance Alliances White Paper]() SPONSOR CRO PHARMACOVIGILANCE ALLIANCES WHITE PAPER whitepaper Jun 21, 2017 Outsourcing pharmacovigilance activities is a standard business practice in a continuously expanding market segment. In the past, outsourced safety services were limited due to concerns about confidentiality, data security, and liability in cases of ... Read More |
| |
![Pharmacy at a glance]() PHARMACY AT A GLANCE whitepaper Jun 20, 2017 For the 2017 survey,the maximum sample size- the number of countries and territories with at least one FIP member organisation or candidate member organisation at the time of the survey. Read More |
![The Pharmaceutical Blockchain of Value Digital Token Launch]() THE PHARMACEUTICAL BLOCKCHAIN OF VALUE DIGITAL TOKEN LAUNCH whitepaper Jun 20, 2017 Drug manufacturers currently do not have an effective way to securely, transparently, and rapidly track the provenance of drugs or to access the data required to combat counterfeit drug sales. (1) As a result, they are unable to decrease the time and... Read More |
![Pharmaceutical Innovation Index 2017]() PHARMACEUTICAL INNOVATION INDEX 2017 whitepaper Jun 14, 2017 The most eye-catching change in innovation for 2016 from the previous year was the fall in the number of new agents approved by the FDA, 22 for 2016 versus 41 and 45 in 2014 and 2015 respectively. Five agents being licensed at the end of 2015, plus t... Read More |
| |
![ANALYSIS OF EXTRACTABLES AND LEACHABLES]() ANALYSIS OF EXTRACTABLES AND LEACHABLES whitepaper Jun 08, 2017 Manufacturers of pharmaceuticals, drug delivery systems, and biomedical devices have come under growing pressure to perform sensitive and accurate analytical studies to detect, identify, and quantify extractable and leachable compounds (E&Ls). E&... Read More |
| |
![Applications in Pharmaceutical Manufacturing]() APPLICATIONS IN PHARMACEUTICAL MANUFACTURING whitepaper May 18, 2017 The use of aqueous cleaning in pharmaceutical manufacturing can provide numerous benefi ts in terms of effectiveness, minimal surface residue, and easier cleaning validation. Virtually any pharmaceutical manufacturing equipment — from tablet
presses... Read More |
![Solving Complex Pharmaceuticals Dosing Tasks]() SOLVING COMPLEX PHARMACEUTICALS DOSING TASKS whitepaper May 18, 2017 In the field of dosing and filling in the pharmaceutical industry, one usually thinks of waterlike, non-viscous products such as solutions used for injecting. For the most part, these can be filled with a high degree of process reliability using hose... Read More |
| |
![White paper - Cancer medicines shortages in Europe]() WHITE PAPER - CANCER MEDICINES SHORTAGES IN EUROPE whitepaper May 17, 2017 Access to medicines for cancer patients is crucial for providing high quality care. However, cancer medicines shortages are a problem affecting countries across Europe. These shortages occur when the supply of medicines, identified as essential by th... Read More |
![Pharmacy’s global transformation is pharma’s opportunity]() PHARMACY’S GLOBAL TRANSFORMATION IS PHARMA’S OPPORTUNITY whitepaper Mar 15, 2017 Pharmacy’s role is expanding from supply chain to primary care, from intermediary and retailer to expert advisor in health and wellness. From the developing nations of India and China to more-developed markets like the UK, this evolution is acc... Read More |
![Chemistry for Better Health]() CHEMISTRY FOR BETTER HEALTH whitepaper Feb 11, 2017 The annual Chemical Sciences and Society Summit (CS3) brings together the best minds in chemical science research from around the world and challenges them to propose innovative solutions for society’s most pressing needs in the areas of health... Read More |
![Pharma & Biotech 2017 – Review of Outsourced Manufacturing]() PHARMA & BIOTECH 2017 – REVIEW OF OUTSOURCED MANUFACTURING whitepaper Jan 26, 2017 This report is an update on the pharmaceutical outsourced manufacturing sector with the last Results’ report published in 2013. By 2015, the global Pharmaceutical market reached $1.11 trillion and is expected to continue growing at approx. 5.5% per a... Read More |
| |
| |
| |
| |
![Pharmaceutical Regulation and Off-Label Uses]() PHARMACEUTICAL REGULATION AND OFF-LABEL USES whitepaper Sep 19, 2016 This White Paper reviews the empirical evidence on pharmaceutical regulation and private investments from the health economics and health policy literature. First, off-label use is defined and the rationale for government regulation is reviewed. The ... Read More |
| |
![Generic and Brand Name Drugs: Understanding the Basics]() GENERIC AND BRAND NAME DRUGS: UNDERSTANDING THE BASICS whitepaper Aug 03, 2016 A brand name drug is a medicine that’s discovered, developed and marketed by a pharmaceutical company. Once a new drug is discovered, the company files for a patent to protect against other companies making copies and selling the drug. At this ... Read More |
| |
| |
![2nd pharmacovigilance 2016]() 2ND PHARMACOVIGILANCE 2016 whitepaper Jul 12, 2016 RecunnectLtd takes the pleasure to invite professionals involved in pharmacovigilance, risk assessment and management, clinical research, data analysis and related fields for a two day conference on Pharmacovigilance to enable them to gain a vantage ... Read More |
![Pharmaceutical Drug Analysis]() PHARMACEUTICAL DRUG ANALYSIS whitepaper Jun 27, 2016 Modern Pharmaceutical Drug Analysis essentially involves as a necessary integral component even greater horizons than the actual prevalent critical analysis of not only the active pharmaceutical substances but also the secondary pharmaceutical produc... Read More |
![Connecting the Dots in Specialty Pharmacy Data]() CONNECTING THE DOTS IN SPECIALTY PHARMACY DATA whitepaper Jun 22, 2016 The rapidly expanding specialty pharmacy market has created unique challenges for pharmaceutical manufacturers looking to obtain dispensing, adherence, and switching data for specialty drugs. Access to timely, anonymized, longitudinal patient data fo... Read More |
| |
| |
| |
![2030 Outlook on sustainability in the biopharma industry]() 2030 OUTLOOK ON SUSTAINABILITY IN THE BIOPHARMA INDUSTRY whitepaper Jun 16, 2016 Sustainalytics is an independent ESG and corporate governance research, ratings and analysis firm supporting investors around the world with the development and implementation of responsible investment strategies. With 14 offices globally, Sustainaly... Read More |
| |
![NTA: Applications in drug delivery]() NTA: APPLICATIONS IN DRUG DELIVERY whitepaper Apr 08, 2016 It is well established that the use of nanotechnology in medicine and more specifically drug delivery is spreading rapidly. Driven by the diminishing rate of discovery of new biologically active compounds that can be exploited therapeutically to trea... Read More |
| |
![Generic Drug Pricing: Understanding the Impact]() GENERIC DRUG PRICING: UNDERSTANDING THE IMPACT whitepaper Nov 13, 2015 The evolution of the generic drug market in recent decades has introduced many benefits to the healthcare industry lower pharmaceutical costs and greater consumer access to needed medicines. By offering the bioequivalent product of a brand name drug ... Read More |
| |
![Marketing the future Which path will you take?]() MARKETING THE FUTURE WHICH PATH WILL YOU TAKE? whitepaper Jul 22, 2015 Published in June 2007 this paper highlights a number of issues that will have a major bearing on the industry over the next 11 years. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the f... Read More |
| |
![Challenging business models Which path will you take?]() CHALLENGING BUSINESS MODELS WHICH PATH WILL YOU TAKE? whitepaper Jun 24, 2015 The pharmaceutical marketplace is undergoing huge changes, as we indicated in “Pharma 2020: The vision”, the White Paper PricewaterhouseCoopers published in June 2007.1 These changes will have a major bearing on the kind of business model... Read More |
| |
| |
| |
| |
| |
![Prescription Drug Management in Workers’ Compensation]() PRESCRIPTION DRUG MANAGEMENT IN WORKERS’ COMPENSATION whitepaper Oct 29, 2014 Prescription drugs have become a key factor in workers’ compensation. Accounting for one of every six medical dollars, pharmacy’s impact on disability duration, return to work and claim settlement outweighs the benefit’s dollar expe... Read More |
![2017 Pharma by numbers]() 2017 PHARMA BY NUMBERS whitepaper Jun 17, 2014 Annual spending by the pharmaceutical industry is 5.5 times greater than the defence and aerospace industries 5 of the 11 leading global R&D firms were research-based pharmaceutical companies In 2014, pharmaceutical industry gross value added was... Read More |
![A White Paper of the American Society of Addiction Medicine]() A WHITE PAPER OF THE AMERICAN SOCIETY OF ADDICTION MEDICINE whitepaper Oct 26, 2013 This White Paper explains the science and current practice of drug testing in various contexts and outlines the ways in which drug testing can be used more effectively in medical practice. We focus on ways that physicians, other health care providers... Read More |
| |
![Crafting an End-to-End Pharma GRC Strategy]() CRAFTING AN END-TO-END PHARMA GRC STRATEGY whitepaper Jun 19, 2013 Understanding the most appropriate regulatory compliance solution extends beyond pure technological functionalities; it requires intimate understanding of policies and procedures required to achieve meaningful compliance with regulations, worldwide. ... Read More |
![The 340b drug discount program]() THE 340B DRUG DISCOUNT PROGRAM whitepaper Oct 30, 2012 Congress created the 340B program in 1992 to help uninsured indigent patients gain better access to prescription medicines. To achieve that goal, Congress created a program that requires pharmaceutical manufacturers to provide discounts on outpatient... Read More |
| |
| |
| |
| |
![Risk Management Programs for the Pharmaceutical Industry]() RISK MANAGEMENT PROGRAMS FOR THE PHARMACEUTICAL INDUSTRY whitepaper Oct 27, 2004 “The FDA oversees the quality of drug products using a two-pronged approach involving review of information submitted in applications as well as inspection of manufacturing facilities for conformance to requirements for current Good Manufacturi... Read More |
| |
![Journal of pharmaceutical and biomedical analysis]() JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS whitepaper This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdi... Read More |
![Pharma experts identify the true cost of product loss]() PHARMA EXPERTS IDENTIFY THE TRUE COST OF PRODUCT LOSS whitepaper These events act as a reminder of how far we have come as an Association but they also remind us of why TAPA is so important and the increasing level of risk facing global supply chains. As we know, there is no finishing line in the fight against org... Read More |
![Achieving Operational Excellence in Pharma & Biotech]() ACHIEVING OPERATIONAL EXCELLENCE IN PHARMA & BIOTECH whitepaper With the pharmaceutical industry currently going through major transformation, improving productivity and reducing costs by implementing Operational Excellence is increasingly important for business success. Pharma and biotech companies can benefit s... Read More |
![Drug Price Forecast Executive Summary July 2017]() DRUG PRICE FORECAST EXECUTIVE SUMMARY JULY 2017 whitepaper This Vizient "Drug Price Forecast" is our best estimate of the change in the cost of pharmaceuticals that Vizient Pharmacy Program participant organizations will purchase between Jan. 1, 2018, and Dec. 31, 2018. The forecast is focused on p... Read More |
![Digital Health in Pharma: Exploring the Potential Impact]() DIGITAL HEALTH IN PHARMA: EXPLORING THE POTENTIAL IMPACT whitepaper Industry experts discuss how digital health is poised to disrupt the pharmaceutical industry and revolutionize the clinical trial process and medication adherence. Digital health – the use of wearables, sensors and applications to remotely coll... Read More |
| |
![Pharmaceutical Innovation Index 2018]() PHARMACEUTICAL INNOVATION INDEX 2018 whitepaper The PII ranks companies by their ability to bring products from Phase I/II to market and commercialize them successfully, and utilizes a range of clinical, regulatory and commercial metrics to do this, ranging from the corporate level down to individ... Read More |
| |
| |
| |
![Clinical research white paper]() CLINICAL RESEARCH WHITE PAPER whitepaper The evolution from scientific hypothesis to approved and marketed medicine is a lengthy and arduous process that typically spans many years of research and development. to understand clinical research and data flows. Read More |
| |
![Cleaning of Medical Device by supercritical CO 2]() CLEANING OF MEDICAL DEVICE BY SUPERCRITICAL CO 2 whitepaper Supercritical CO2 has the characteristics of both a liquid and a gas. Like a gas, it diffuses rapidly, has low viscosity, near zero surface tension, and thus, penetrates easily into deep trenches and porosities allowing more effective cleaning. Like ... Read More |
![A Scowcroft Institute of International Affairs]() A SCOWCROFT INSTITUTE OF INTERNATIONAL AFFAIRS whitepaper The threat posed by pandemics grows alongside increased globalization and technological innovation. Distant cultures can now be connected in a day’s time, and international trade links global health and economic prosperity. In this report, the ... Read More |
![Pharmaceutical policy in China]() PHARMACEUTICAL POLICY IN CHINA whitepaper Pharmaceuticals make a significant contribution to the health and well-being of a population and government policy regarding pharmaceuticals exerts a significant effect on the state of the pharmaceutical market. Governments generally have several obj... Read More |
![A Case for Small Cap Investing: Biotech]() A CASE FOR SMALL CAP INVESTING: BIOTECH whitepaper In this paper, we sought to lay out the rationale for investing in small cap biotech. There are two key drivers of stock performance of small cap biotech: clinical data and acquisitions. As clinical data must be analyzed on a case-by-case basis, we h... Read More |
| |
![Precision Material Creates New Applications and Markets]() PRECISION MATERIAL CREATES NEW APPLICATIONS AND MARKETS whitepaper Another common porous silica material, developed in the late 1990’s at the University of California at Santa Barbara, is SBA-15. Similar to MCM-41, it is relatively low cost to produce and has controllable pore diameters. But relative to MCM-41... Read More |
| |
| |
![A New Pharmaceutical Commons: Transforming Drug Discovery]() A NEW PHARMACEUTICAL COMMONS: TRANSFORMING DRUG DISCOVERY whitepaper The Oxford Martin School at the University of Oxford is a worldleading centre of pioneering research that addresses global challenges. We invest in research that cuts across disciplines to tackle a wide range of issues such as climate change, disease... Read More |
![Porous Silica Creates New Applications and Markets]() POROUS SILICA CREATES NEW APPLICATIONS AND MARKETS whitepaper Pharmaceutical and nutraceutical companies have identified product identification (PI) as a major focus to identify and deter counterfeiting and product diversion. This is done through track and trace technologies. To date, the majority of the PI has... Read More |
![Pharmaceutical Cleaning Validation]() PHARMACEUTICAL CLEANING VALIDATION whitepaper Cleaning validation is a necessary and time-consuming part of manufacturing pharmaceuticals. The validation process can be expedited and the cost reduced if the cleaner supplier can provide support — ultimately allowing pharmaceuticals to get t... Read More |
![Harnessing innovative technologies]() HARNESSING INNOVATIVE TECHNOLOGIES whitepaper Introduction: The rise of the super-bug in today’s world, the biodiversity of vital ecosystems is threatened by factors, such as overpopulation, deforestation, mass migrations, war, famine, depletion of natural resources and animal-human intera... Read More |
![TUBERCULOSIS Diagnostics Technology Landscape]() TUBERCULOSIS DIAGNOSTICS TECHNOLOGY LANDSCAPE whitepaper The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area ... Read More |
| |
| |
| |
![Raman monitoring of active coating composition]() RAMAN MONITORING OF ACTIVE COATING COMPOSITION whitepaper Pharmaceutical tablets are coated for a variety of reasons, such as to enhance the appearance, taste, chemical stability, or swallowability of the tablet or to create a particular release profile for the active pharmaceutical ingredient (API). Recent... Read More |
![2018 Pharma Quality Outlook]() 2018 PHARMA QUALITY OUTLOOK whitepaper In this report, Sparta Systems, a quality management system (QMS) software provider, examines the results of a Pharmaceutical Technology survey of 160 respondents. The survey was designed to explore the evolving function of pharmaceutical quality man... Read More |
![Cleaning Validation for Pharmaceutical Manufacturing]() CLEANING VALIDATION FOR PHARMACEUTICAL MANUFACTURING whitepaper Cleaning validation is a requirement in industries such as pharmaceutical manufacturing that adhere to current Good Manufacturing Practice (cGMP) and Quality Systems Regulations (QSR). It is specifi c to the cleaning method and cleaner employed. Simp... Read More |
| |
| |
![Raman monitoring of active coating composition]() RAMAN MONITORING OF ACTIVE COATING COMPOSITION whitepaper Recently a technique called active coating has become more common in the pharmaceutical processing industry. In active coating, the API is included in the tablet’s coating in order to create a multi-step release profile for a single API or to s... Read More |
| |
![A basic guide to particle characterization]() A BASIC GUIDE TO PARTICLE CHARACTERIZATION whitepaper The aim of this guide is to provide you with a basic grounding in the main particle characterization techniques currently in use within industry and academia. It assumes no prior knowledge of particle characterization theory or instrumentation and sh... Read More |
![Pharmaceutical Industry Outlook 2016]() PHARMACEUTICAL INDUSTRY OUTLOOK 2016 whitepaper Tougher competition and margin pressures create more challenges for the pharma industry in 2016. As more physicians are graduating med school to work directly for a health system instead of opening their own practice, sales force is struggling to ada... Read More |
| |
![Chemical and Pharmaceutical Industry on the Rise]() CHEMICAL AND PHARMACEUTICAL INDUSTRY ON THE RISE whitepaper The chemical industry is one of the most demanding branches in terms of capital investment, and in view of its complicated production processes and technologies, it requires a highly skilled workforce and considerable investment in research and devel... Read More |
![U.S. Government Zika Vaccine Strategy]() U.S. GOVERNMENT ZIKA VACCINE STRATEGY whitepaper To address the Zika virus public health threat, the Departments of Health and Human Services and Defense2F 1 are coordinating efforts to help accelerate the development of Zika virus vaccines. Given the need for a vaccine to prevent disease caused by... Read More |
![Quality of 3M Canada Drug Products]() QUALITY OF 3M CANADA DRUG PRODUCTS whitepaper Recent reports of intrinsic contamination of drug products, including skin antiseptics in the United States have focused attention on the importance of strict adherence to established good manufacturing processes and the application of quality assura... Read More |
| |
![Pharmaceutical Line Extensions in the United States]() PHARMACEUTICAL LINE EXTENSIONS IN THE UNITED STATES whitepaper Innovative pharmaceutical companies engage in sophisticated strategies to moderate the loss of revenue they will face when generic competitors enter the market. Known in the industry as product lifecycle management, these strategies often rely on the... Read More |
![AN ANALYSIS OF DRUG THERAPY TAPERING GUIDELINES]() AN ANALYSIS OF DRUG THERAPY TAPERING GUIDELINES whitepaper Chronic pain, the kind of pain a person wakes up with every morning and goes to sleep with every night, has a standard of care that is often incomplete and sometimes inaccurate. Chronic pain treatment often revolves around drug therapy and managing s... Read More |
![Managing The Costs Of Specialty Drugs]() MANAGING THE COSTS OF SPECIALTY DRUGS whitepaper While the term “specialty drugs” has no standard definition, these pharmaceuticals are universally associated with high costs and complex conditions. Unique and highly targeted, such drugs can provide significant improvement or even a cur... Read More |
| |
![Pharma outlook 2030: From evolution to revolution]() PHARMA OUTLOOK 2030: FROM EVOLUTION TO REVOLUTION whitepaper The pharmaceutical sector is at a crossroads. In a heavily disrupted marketplace, characterized by shifting payer attitudes and patient empowerment, neither incremental adjustments nor steady evolution is likely to halt the decline of the traditional... Read More |
![Prescription Drug Abuse and Prevention]() PRESCRIPTION DRUG ABUSE AND PREVENTION whitepaper America is in the midst of a prescription opioid epidemic. It is estimated that in 2016, 11.8 million Americans, or 4.4 percent of the population, age 12 years and older were nonmedical users of opioids – defined as prescription pain relievers ... Read More |
![Prescription Drug Abuse]() PRESCRIPTION DRUG ABUSE whitepaper Deaths from drug overdose have been rising steadily over the past two decades and have become the leading cause of injury death in the United States. Every day in the United States, 114 people die as a result of drug overdose, and another 6,748 are t... Read More |
| |
| |
| |
| |
| |
![The Rebirth Of The Pharmaceutical Sales Force]() THE REBIRTH OF THE PHARMACEUTICAL SALES FORCE whitepaper At Accenture, we believe the healthcare industry’s focus on delivering improved patient outcomes, along with advances in digital technologies, create an environment in which sales reps will be more valuable than ever. With new skills and digita... Read More |
| |
| |
| |
![2015 profile biopharmaceutical Research Industry]() 2015 PROFILE BIOPHARMACEUTICAL RESEARCH INDUSTRY whitepaper Biopharmaceutical companies make the medicines that save and improve patients’ lives every day. Patients often rely on medicines to keep their symptoms at bay and allow them to continue to work and live healthy, productive lives. Others rely on... Read More |
| |
| |
| |
| |
![Medical Device Home Use Initiative]() MEDICAL DEVICE HOME USE INITIATIVE whitepaper Assuring the safety and safe use of medical devices in the home is becoming an increasingly important public health issue. The aging of the U.S. population and shifts toward shorter hospital stays continue to make home healthcare more common. With th... Read More |
| |
| |
![IBM Solution for Pharmaceutical Track & Trace]() IBM SOLUTION FOR PHARMACEUTICAL TRACK & TRACE whitepaper At its core, the pharmaceutical industry is about improving the quality of people’s lives. But today’s life-saving drugs are often small, high-value items which are easily stolen or diverted. Nearly impossible to authenticate by the end u... Read More |
| |
| |
| |
| |
| |
| |
![Model-based Drug Development for Generic Products]() MODEL-BASED DRUG DEVELOPMENT FOR GENERIC PRODUCTS whitepaper As a generic drug manufacturer, the goal of your product development program is to demonstrate bioequivalence of your product to the branded product. Often a straightforward trial and error process based on the experience of the formulation team has ... Read More |
| |
| |
| |
| |
| |
| |
![Production processes in the pharmaceutical industry]() PRODUCTION PROCESSES IN THE PHARMACEUTICAL INDUSTRY whitepaper A great source of worry in industrialized societies is disease or health problems caused by taking medicines that are in poor condition or are subject to a health alert. Society expects that manufacturers, distributors, and employees should be in con... Read More |
| |
![FDA Pharmaceutical Quality Oversight One Voice]() FDA PHARMACEUTICAL QUALITY OVERSIGHT ONE VOICE whitepaper The launch of the Center for Drug Evaluation and Research (CDER) Office of Pharmaceutical Quality (OPQ) is a milestone in FDA’s efforts to assure that quality medicines are available to the American public. As a new super-office within CDER, OP... Read More |
![Your partner for oral drug delivery services]() YOUR PARTNER FOR ORAL DRUG DELIVERY SERVICES whitepaper To meet your requirements even better, we have created a specific range of drug delivery technologies, EUDRATEC. For both EUDRAGIT and EUDRATEC we offer tailor-made development services for commercially viable formulations. We develop and manufa... Read More |
![We make drugs smarter]() WE MAKE DRUGS SMARTER whitepaper Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities to create value for our pharmaceutical partners by providing a complete portfolio of integrated drug delivery servi... Read More |
![Pharmaceutical Serialization: An Implementation Guide]() PHARMACEUTICAL SERIALIZATION: AN IMPLEMENTATION GUIDE whitepaper Global pharmaceutical companies lose an estimated $75 billion annually to counterfeit, gray market and stolen product. Impending regulations aimed at protecting public health, intellectual property and national security will require pharmaceutical, m... Read More |
![Pharmaceutical Serialization Track & Trace]() PHARMACEUTICAL SERIALIZATION TRACK & TRACE whitepaper Pharmaceutical Companies have to contend with challenges stemming from supply chain security lapses (Resulting in theft, diversion, and product RE calls), Counterfeiting stringent regulation. Read More |
![Value-based pricing in pharmaceuticals]() VALUE-BASED PRICING IN PHARMACEUTICALS whitepaper Value-based pricing (VBP) of pharma products has exciting potential to help improve patient outcomes – at an affordable cost. The concept of VBP has been around for some time, but healthcare stakeholders are still grappling with what it means f... Read More |
![Fundamentals of Spray-Dried Dispersion Technology]() FUNDAMENTALS OF SPRAY-DRIED DISPERSION TECHNOLOGY whitepaper A common problem statement in the pharmaceutical industry is low oral bioavailability of drug candidates with poor aqueous solubility. The literature suggests that a significant majority of new drug candidates are in the Biopharmaceutics Classificati... Read More |
| |
![Embracing China’s brave new pharmaceutical world]() EMBRACING CHINA’S BRAVE NEW PHARMACEUTICAL WORLD whitepaper Sales of pharmaceuticals in China are already the third highest in the world, and China is likely to become the world’s second-largest drug market within the next year. Multinational pharmaceutical corporations cannot afford to underperform in ... Read More |
![Pharmaceutical Waste Management]() PHARMACEUTICAL WASTE MANAGEMENT whitepaper Every day, healthcare organizations dispense a broad spectrum of medications. An essential yet often overlooked aspect of this drug delivery process is what to do with any unused medications. Read More |
| |
![Specialty Drug Spending]() SPECIALTY DRUG SPENDING whitepaper The IMS Institute for Healthcare Informatics reported that spending on specialty pharmaceuticals almost doubled from 2010 to 2015, and spending on this subset of drugs was responsible for 70% of overall drug spending growth during this timeframe. Read More |
| |
![Pharmaceutical Freeze Drying Technology]() PHARMACEUTICAL FREEZE DRYING TECHNOLOGY whitepaper Although it is one of the oldest techniques in the pharmaceutical industry for the preservation of unstable materials, there still is an increased demand for lyophilized products and equipment. To accommodate such a growth, the freeze-drying process ... Read More |
![Tamper-proof Pharmaceutical Packaging]() TAMPER-PROOF PHARMACEUTICAL PACKAGING whitepaper There is hardly another product that reaches consumers or patients for which packaging requirements are as varied as for pharmaceutical products. The »Poisons Prevention Packaging Act« (PPPA) enacted in the United States back in 1970 addr... Read More |
![How Machine Vision Cameras Help Medicine]() HOW MACHINE VISION CAMERAS HELP MEDICINE whitepaper Cameras have been playing an increasingly important role in medicine for many years now. Regardless of whether you‘re looking at medical devices, laboratory automation or the operating room, in almost every field there is a multitude of everyda... Read More |
![Drug Branding Through the Eyes of the Consumer]() DRUG BRANDING THROUGH THE EYES OF THE CONSUMER whitepaper Pharmaceutical drug naming and branding can seem like a complicated mystery to most consumers. Because of extensive research and regulations, medication names are getting less and less intuitive but marketed more than ever. It wasn’t too long a... Read More |
| |
![Public procurement of medicinal products]() PUBLIC PROCUREMENT OF MEDICINAL PRODUCTS whitepaper The purpose of this white paper is to provide an overview of the applicability of public procurement legislation in the healthcare sector, and more specifically the challenges it sets to the pharmaceutical industry. Read More |
| |
![for Laser Marking in Pharmaceutical Applications]() FOR LASER MARKING IN PHARMACEUTICAL APPLICATIONS whitepaper The Drug Quality and Security Act, a United States bill passed in 2013, calls for manufacturers to make prescription drugs traceable on a per-unit basis. Manufacturers will need to mark each package with a serial number or machine-readable code in or... Read More |
![Vitamins for pharmaceutical applications]() VITAMINS FOR PHARMACEUTICAL APPLICATIONS whitepaper Micronutrients play a critical role in overall nutrition and health. This is highlighted by the plethora of continuous research published in high profile scientific journals focused on the benefits of vitamins and minerals. However, evidence shows th... Read More |
| |
| |
| |
![BREAST CANCER DRUGS FUNDING AND TRIALS]() BREAST CANCER DRUGS FUNDING AND TRIALS whitepaper Pink Ribbon is a growing international network for breast cancer prevention and cure, seeking to help eliminate all breast cancer-related deaths. In the UK, its current focus includes an annual conference called the Breast Cancer Forum, held in assoc... Read More |
![Vaccine Safety]() VACCINE SAFETY whitepaper This white paper provides an introduction to vaccine safety science and policy in the United States. Section “I” discusses how Congress granted pharmaceutical companies immunity from liability for vaccine injuries and transferred all resp... Read More |
![Procurement’s Impact on Pharma in 2016]() PROCUREMENT’S IMPACT ON PHARMA IN 2016 whitepaper Within the highly regulated pharmaceutical industry, pipeline activity is fueled by M&A and drug development. This process is drawn out by lengthy phases of research and discovery as well as risky clinical trials. For pharma companies (and by ext... Read More |
![Manufacturing Injectables in the Multiplex]() MANUFACTURING INJECTABLES IN THE MULTIPLEX whitepaper Today, pharmaceutical companies need to produce a higher number of therapeutics for smaller patient populations. But as the FDA points out, companies have not invested in manufacturing infrastructure and practices to meet these challenges. The goal o... Read More |
| |
| |
| |
| |
| |
| |
| |
| |
| |
![Ten Tips for Single Use Pharmaceutical Tubing Selection]() TEN TIPS FOR SINGLE USE PHARMACEUTICAL TUBING SELECTION whitepaper Tubing used in pharmaceutical and biotech applications has particular requirements. Among them are the ability to withstand sterilization processes, the delivery of favorable test results regarding extractable substances, and the absence of animal de... Read More |
| |
![Applications in Pharmaceutical Manufacturing]() APPLICATIONS IN PHARMACEUTICAL MANUFACTURING whitepaper The use of aqueous cleaning in pharmaceutical manufacturing can provide numerous benefits in terms of effectiveness, minimal surface residue, and easier cleaning validation. Virtually any pharmaceutical manufacturing equipment, from tablet presses to... Read More |
| |
![Paperless manufacturing in the pharmaceutical industry]() PAPERLESS MANUFACTURING IN THE PHARMACEUTICAL INDUSTRY whitepaper With growing cost pressures and new regulations, manufacturers and quality managers in the pharmaceutical industry are always looking for ways to improve their processes and procedures. A new electronic batch record solution enables complete paperles... Read More |
| |
| |
![PLM for Pharmaceutical Industry]() PLM FOR PHARMACEUTICAL INDUSTRY whitepaper The Pharmaceutical industry holds an undeniably important place in the Life Sciences sector world-wide as it is solely responsible for designing and manufacturing lifesaving drugs and medications. The revenue from this industry alone has almost touch... Read More |
![Convergence of Health and Pharma]() CONVERGENCE OF HEALTH AND PHARMA whitepaper Traditionally, the healthcare and pharmaceutical industries have followed a conventional supplier-consumer relationship. However, both industries face the same core challenge to deliver better health outcomes at lower cost. This paper discusses chall... Read More |
![Pharmaceutical Hard Capsule Dissolution Equivalence]() PHARMACEUTICAL HARD CAPSULE DISSOLUTION EQUIVALENCE whitepaper Empty hard capsules are widely used as a dosage delivery system in the pharmaceutical industry. Gelatin or Hypromellose (HPMC) are used as the shell raw material in the majority of pharmaceutical applications for various reasons including their uniqu... Read More |
| |
![Regulatory Compliance: Weighing in Pharma Manufacturing]() REGULATORY COMPLIANCE: WEIGHING IN PHARMA MANUFACTURING whitepaper The Pharma IQ survey depicts the trend of increasingly stringent regulations in the pharmaceutical industry. However, regulations usually only provide broad guidance (e.g. measuring devices must be calibrated) and leave it to the manufacturer to defi... Read More |
| |
| |
![Precision Medicine: The New R&D Paradigm]() PRECISION MEDICINE: THE NEW R&D PARADIGM whitepaper The drug that can be considered the first precision medicine entered the market in 1998, at a time when the concept was referred to as personalized medicine. Herceptin (trastuzumab) was first used for the treatment of a subgroup of breast cancer pati... Read More |
![Creating New Value for Biopharma]() CREATING NEW VALUE FOR BIOPHARMA whitepaper In this paper we envisage future opportunities for value creation by the global biopharma industry. We set these opportunities in the context of an evolving healthcare ecosystem which continually creates new business opportunities and challenges for ... Read More |
| |
![Future Trends In Pharmaceutical and Biotech Distribution]() FUTURE TRENDS IN PHARMACEUTICAL AND BIOTECH DISTRIBUTION whitepaper This research study was oriented primarily around the Pharmaceutical and Biotech distribution sector. We focused on the analysis of the current situation and the likely changes in this industry in the next 3 to 5 years. At the outset of the study, we... Read More |
| |
![Market access for medical devices: Challenges and potential Solutions]() MARKET ACCESS FOR MEDICAL DEVICES: CHALLENGES AND POTENTIAL SOLUTIONS whitepaper According to the World Health Organization (WHO) definition, a medical device is “an article, instrument, apparatus, or machine that is used in the prevention, diagnosis, or treatment of illness or disease, or for detecting, measuring, restoring, cor... Read More |
![Modern Drug Commercialization]() MODERN DRUG COMMERCIALIZATION whitepaper In today's pharmaceutical market, it often takes more than a decade and an estimated $2.6 billion to bring a new drug to market. The long development lead time result in approximately 7 to 10 year of patent protection before generic competition launc... Read More |
![Improving the Quality of Generic Drugs]() IMPROVING THE QUALITY OF GENERIC DRUGS whitepaper This white paper addresses key policy issues, best practices, and key challenges around the pharmaceutical value chain that has an impact on quality of pharmaceuticals available to patients. This white paper also discusses the key stakeholders involv... Read More |
![Medical Information Role in the Pharmaceutical Industry]() MEDICAL INFORMATION ROLE IN THE PHARMACEUTICAL INDUSTRY whitepaper Medical information (MI) teams at pharmaceutical and medical device companies primarily respond to inquiries about the company’s products. Inquiries can originate from healthcare providers, patients, scientists or anyone interested in information abo... Read More |
| |
| |
| |
![Pharmaceutical Manufacturing]() PHARMACEUTICAL MANUFACTURING whitepaper The manufacture of ethical pharmaceutical products is a critically important process in the provision of healthcare. The process is both technical and carefully regulated, and staff ed by highly trained professionals, and thus the business enjoys hig... Read More |
| |
![Stability Testing of Biopharmaceuticals.]() STABILITY TESTING OF BIOPHARMACEUTICALS. whitepaper Stability testing of a drug substance or a finished product is a vital part of the data package submitted in support of new drug applications or marketing authorisations. The principle ethos of stability testing is to provide evidence to a regulatory... Read More |
![Realising the potential of stratified medicine]() REALISING THE POTENTIAL OF STRATIFIED MEDICINE whitepaper Although patient treatment has always been personalised by clinicians based upon individual circumstance and medical history, advances in our understanding of the molecular basis of diseases are redefining how diseases are classified and present a po... Read More |
| |
![Boost field IQ to increase pharmaceutical sales]() BOOST FIELD IQ TO INCREASE PHARMACEUTICAL SALES whitepaper The more sales reps know about the physicians in their territory, the better their leverage in gaining access to them, which is why one top 10 pharmaceutical company decided to focus on enhancing field intelligence. They turned to LexisNexis Health C... Read More |
| |
![Finding and Executing Pharma Licensing Opportunities]() FINDING AND EXECUTING PHARMA LICENSING OPPORTUNITIES whitepaper It is not surprising that mostly small to medium sized companies seek the help of specialist consultancies to find commercial partners or find in-licensing opportunities. Large pharma is in the attractive position that they get thousands of unsolicit... Read More |
| |
| |
![Biopharmaceuticals In Perspective]() BIOPHARMACEUTICALS IN PERSPECTIVE whitepaper This chart pack provides facts and figures about prescription medicines and their role in the health care system. Topics include medicines’ impact on health and quality of life, the drug discovery and development process, health care spending and cos... Read More |
| |
| |
| |
![Stars in Our Eyes Ophthalmology Drugs Report]() STARS IN OUR EYES OPHTHALMOLOGY DRUGS REPORT whitepaper The ophthalmology drug segment continues to shine brightly with a number of deals announced in November such as Genentech’s partnering with Novartis to split ex-US rights to Ophthotech’s eye drug, which could be worth more than $1 billion. Allergan, ... Read More |
| |
| |
![Moving to Specialty Pharma: How to Succeed]() MOVING TO SPECIALTY PHARMA: HOW TO SUCCEED whitepaper The Pharma industry is increasing its focus on developing Specialty drugs. It is expected to grow by 67% in 2015 alone, while the overall Specialty drug spending is expected to more than quadruple by 2020, accounting for about $402 billion a year in ... Read More |
![Streamlining Pharma Drug Development]() STREAMLINING PHARMA DRUG DEVELOPMENT whitepaper The costs of drug development continue to rise. Dramatically. According to a 2015 report by Deloitte, costs have increased by a third in just the last five years. If that weren’t trouble enough, sales during the same time frame have tumbled 50%. Incr... Read More |
| |
![Big Data Breathes Life into Next-Gen Pharma R&D]() BIG DATA BREATHES LIFE INTO NEXT-GEN PHARMA R&D whitepaper The process of drug development is lengthy and complex combined with several processes, applications and approvals. Unquantified and unstructured data is produced from multiple systems in various forms. However, recent advances in storage, network an... Read More |
![Pharmaceutical packaging serialization]() PHARMACEUTICAL PACKAGING SERIALIZATION whitepaper Packaging standards are growing in complexity as manufacturers serve an increasingly global customer base, and serialization requirements continue to be deployed across a number of countries. Life sciences packaging needs have driven innovation in th... Read More |
![Process PLM: The Future of Pharmaceutical Manufacturing]() PROCESS PLM: THE FUTURE OF PHARMACEUTICAL MANUFACTURING whitepaper It’s been over a dozen years since The Wall Street Journal famously observed that pharmaceutical manufacturing techniques lagged “far behind those of potato-chip and laundry-soap makers.”1 The same publication made a similarly stark observation just ... Read More |
| |
![Oncology Drug Development and Value-Based Medicine]() ONCOLOGY DRUG DEVELOPMENT AND VALUE-BASED MEDICINE whitepaper Cancer drugs constitute the second biggest category of drugs sold in the U.S. Worldwide, sales of cancer drugs are forecast to grow steadily, driven by the aging population and by opportunities for earlier therapeutic intervention using more effectiv... Read More |
| |
| |
![A NEW PARADIGM FOR MANUFACTURING INJECTABLE MEDICINES]() A NEW PARADIGM FOR MANUFACTURING INJECTABLE MEDICINES whitepaper The drug they were making was a predecessor of today’s therapies. It was complex, high-value and hard to manufacture. Seeing that pharmaceutical companies’ drug discovery platforms were swelling the ranks of clinical product candidates, they could se... Read More |
![Human Error in Pharmaceutical Manufacturing]() HUMAN ERROR IN PHARMACEUTICAL MANUFACTURING whitepaper Human Error frequently occurs in pharmaceutical manufacturing, even when the organisation considers that they have done everything to prevent its occurrence. Documentation appears accurate, personnel are fully trained and equipment operates as design... Read More |
| |
| |
![The changing biopharma risk equation]() THE CHANGING BIOPHARMA RISK EQUATION whitepaper As pharma companies expand, they are looking more and more to biologics for their next potential blockbusters. However, this class of product ranging from well-established large molecule drugs to truly novel therapies poses major challenges because o... Read More |
| |
| |
| |
![The importance of COPQ for the pharmaceutical industry]() THE IMPORTANCE OF COPQ FOR THE PHARMACEUTICAL INDUSTRY whitepaper As any senior executive within an organisation knows, the reduction of waste and, more importantly, the cost associated with that waste can have a major effect on any business. Whilst some waste is unavoidable, an executive can begin to implement pri... Read More |
![Perfect climate for pharmaceutical manufacture]() PERFECT CLIMATE FOR PHARMACEUTICAL MANUFACTURE whitepaper Pharmadule, the world leader in modular manufacturing facilities for the pharmaceutical industry, has in recent years been working with Munters to supply humidity controlled facilities for Eli Lilly Indianapolis, Baxter Bloomington USA and Eli Lilly ... Read More |
| |
| |
| |
![Origin Hybrid Pharmaceutical Packaging (HP3) Brochure]() ORIGIN HYBRID PHARMACEUTICAL PACKAGING (HP3) BROCHURE whitepaper Origin’s ethos is everything we do, we innovate. Whether that is a new child resistant closure for a major pharmaceutical company, to a new, state of the art Enterprise Resource Planning System to further improve the customer’s experience with Origin... Read More |
![Addressing the Challenges of Pharmaceutical Content]() ADDRESSING THE CHALLENGES OF PHARMACEUTICAL CONTENT whitepaper As demographics change, and more and more new pharmaceutical and medical devices come to market, content plays an increasingly important role in regulatory requirements, and physician and patient knowledge and support. Yet content is still created an... Read More |
| |
![Turkish Pharmaceutical Market]() TURKISH PHARMACEUTICAL MARKET whitepaper Ranked as the 16th largest pharmaceutical market in the world and the seventh biggest in Europe in 2011 in terms of sales, Turkey's domestic market offers many opportunities. According to data from the Association of Research-Based Pharmaceutical Com... Read More |
| |
| |
![Is pharma brand marketing dead?]() IS PHARMA BRAND MARKETING DEAD? whitepaper That is the provocative question I have been posing to pharmaceutical marketers, industry leaders and stakeholders over the last few months. This supplement brings together a series of articles, insights and discussions Kantar Health has produced in ... Read More |
| |
![Recognising The Needs Of The Pharmaceutical Industry]() RECOGNISING THE NEEDS OF THE PHARMACEUTICAL INDUSTRY whitepaper Catalysis is an essential part of many pharmaceutical processes. With increasing innovation in catalytic chemistry coupled with ever increasing regulatory requirements for residual levels of metal catalysts, particularly Platinum and Palladium, the r... Read More |
| |
| |
| |
| |
| |
![Stars in Our Eyes Ophthalmology Drugs Report]() STARS IN OUR EYES OPHTHALMOLOGY DRUGS REPORT whitepaper The ophthalmology drug segment continues to shine brightly with a number of deals announced in November such as Genentech’s partnering with Novartis to split ex-US rights to Ophthotech’s eye drug, which could be worth more than $1 billion. Allergan, ... Read More |
| |
| |
| |
| |
| |
![Delivering on the Potential of Biosimilar Medicines]() DELIVERING ON THE POTENTIAL OF BIOSIMILAR MEDICINES whitepaper Realizing this potential is neither easy nor assured. The lack of uniformity across EU nations that have had access to biosimilar medicines for almost a decade suggests the underlying elements of achieving the full potential from biosimilar medicines... Read More |
| |
![Pharmaceutical Marketing]() PHARMACEUTICAL MARKETING whitepaper it’s been almost 15 years since U.S. direct-to-consumer advertising regulations were loosened. And in those years, the consumer pharmaceutical marketing industry has gone from about $700 million in ad spending to a peak of $5.4 billion in 2006. Spend... Read More |
![Mastering Change in Inhalation Drug Delivery]() MASTERING CHANGE IN INHALATION DRUG DELIVERY whitepaper The first evidence of humans smoking Atropa Belladonna as a cough remedy can be dated back over 4,000 years. Fortunately, technology and expertise in inhalation drug delivery have improved significantly since then, offering better predictability, eff... Read More |
![Value Added Medicines]() VALUE ADDED MEDICINES whitepaper The current pool of existing molecules potentially re-positioned, re-formulated or combined with new technological platforms and services might offer therapeutic alternatives and opportunities for patients and health care systems. Even if this concep... Read More |
| |
![Continued Development of Approved Biological Drugs]() CONTINUED DEVELOPMENT OF APPROVED BIOLOGICAL DRUGS whitepaper As the U.S Congress considers creating a process that allow the FDA to approve follow -on biologics (FOBs) also referred to as biosimilars on the basis of an abbreviated application by follow on manufacturers there has been heightened interest in und... Read More |
![The Journal of Human Pharmacology and Drug Therapy]() THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY whitepaper This White Paper examines the pharmacy profession’s future. It discusses pharmacy’s changing philosophy of practice, factors influencing the evolution of professional roles and responsibilities, preparation for future roles, future leadership and man... Read More |
| |
| |
| |
![Selecting a Dosage Form for Drug Delivery to the Lungs]() SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS whitepaper Salt form screening (if applicable) is an important early step in inhalation dosage form selection. Approximately 50% of active pharmaceutical ingredients (APIs) in approved products are salt forms,1 and that proportion is slightly higher (approx. 60... Read More |
![Pharmaceutical Development for ADCs: Not as Simple as ABC]() PHARMACEUTICAL DEVELOPMENT FOR ADCS: NOT AS SIMPLE AS ABC whitepaper Formulation, process, and analytical development for antibody-drug conjugates, or ADCs, is complex. While the development of an aqueous solution formulation may be preferred over a lyophilized product, it is useful to initially pursue a dual path and... Read More |
![Drug Nanocarriers]() DRUG NANOCARRIERS whitepaper The role that nanoparticles play in the rapidly developing field of ‘NanoMedicine’ has been discussed previously in Chapter 5. In this Chapter, we review the specificmechanisms by which such nanoparticles are designed and formulated and in which NTA ... Read More |
| |
| |
| |
![Guide to Pharmaceutical Serialization 2017]() GUIDE TO PHARMACEUTICAL SERIALIZATION 2017 whitepaper The entire pharmaceutical supply chain, including drug manufacturers, wholesale drug distributors, repackagers, and many dispensers (primarily pharmacies), have been called upon to act within their respective portion of the supply chain. An initiativ... Read More |
| |
![A Cure for Pharmaceutical Supply Chain Complexity]() A CURE FOR PHARMACEUTICAL SUPPLY CHAIN COMPLEXITY whitepaper The pharmaceutical industry lags in the sophistication and performance of its supply chains when they are compared with best-in-class companies in other industries. This is due to the complexity that has come with new drugs, more complex production t... Read More |
![DSCSA IMPLEMENTATION FOR PHARMACEUTICAL 3PL PROVIDERS]() DSCSA IMPLEMENTATION FOR PHARMACEUTICAL 3PL PROVIDERS whitepaper With the stroke of a pen in 2013, the pharmaceutical industry mobilized in order to comply with sweeping changes enacted by the Drug Quality and Safety Act. The law includes the Drug Supply Chain Security Act (“DSCSA”), written to increase patient sa... Read More |
![Pharmaceutical Waste Management]() PHARMACEUTICAL WASTE MANAGEMENT whitepaper The EPA’s recent focus on pharmaceutical waste management has been influenced by increasing evidence of pharmaceuticals in drinking water. An Associated Press series on pharmaceutical waste in May 2009, reported that EPA has found traces of pha... Read More |
| |
![Solutions for the future of biomanufacturing]() SOLUTIONS FOR THE FUTURE OF BIOMANUFACTURING whitepaper The biomanufacturing industry is undergoing a major shift, from single-product processes and stainless-steel infrastructure to flexible, multi-product facilities using single-use technology. Though single-use is being widely adopted, there still exis... Read More |
![Almac: Crystallisation of Pharmaceutical Compounds]() ALMAC: CRYSTALLISATION OF PHARMACEUTICAL COMPOUNDS whitepaper The Almac Group provides development and manufacturing services for Active Pharmaceutical Ingredients (APIs) to pharmaceutical industries worldwide. Over the past 40 years, we have made numerous discoveries that have become powerful intellectual prop... Read More |
| |
| |
| |
| |
![2016 State of Drug Development: From Molecule to Market]() 2016 STATE OF DRUG DEVELOPMENT: FROM MOLECULE TO MARKET whitepaper Drug development is an area of high risk, but it also has potential to be of high reward. Developers can create therapeutics that have an enormously positive impact on outcomes for patients, reduce the burden on healthcare and create return on invest... Read More |
![High Potency Drugs – from Molecule to Market]() HIGH POTENCY DRUGS – FROM MOLECULE TO MARKET whitepaper PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30... Read More |
![The Pharmaceutical Innovation Platform]() THE PHARMACEUTICAL INNOVATION PLATFORM whitepaper Global progress in addressing people’s health needs over the past century has been nothing short of spectacular. Many factors have contributed to this improvement, but one has been particularly critical: advances in medical technologies from the priv... Read More |
| |
| |
| |
| |
![Thermal Analysis with Pharmaceutical Applications]() THERMAL ANALYSIS WITH PHARMACEUTICAL APPLICATIONS whitepaper Thermal analysis techniques are used to characterize the properties of crystalline solids and identify polymorphs. These techniques can also be used to study the effects of lyophilization on a test material. Differential scanning calorimetry (DSC) an... Read More |
| |
| |
| |
![SOLVING THE KNOWLEDGE MANAGEMENT PUZZLE IN BIOPHARMA]() SOLVING THE KNOWLEDGE MANAGEMENT PUZZLE IN BIOPHARMA whitepaper In the ever-quickening quest for knowledge, a diversity of biopharma professionals are driven by a multiplicity of agendas spanning research to regulation. From the seeking of medical breakthroughs to the preparation of FDA submissions; from clinical... Read More |
| |
| |
| |
![Contract Manufacturing of Biopharmaceuticals]() CONTRACT MANUFACTURING OF BIOPHARMACEUTICALS whitepaper Biovian is a one-stop-shop in GMP contract manufacturing
of biopharmaceuticals covering services from early development to finished vial. Biovian’s 2700 m2 facilities are
EMA and FDA certified for GMP production of investigational and commercial m... Read More |
![Innovating For better Health]() INNOVATING FOR BETTER HEALTH whitepaper Our Innovating for Improvement programme aims to improve health care delivery and/or the way people manage their own health care through the redesign of processes, practices and services. We support clinical teams to develop their innovative ideas an... Read More |
| |
![Nasal Drug Delivery Devices and Pain Management Systems]() NASAL DRUG DELIVERY DEVICES AND PAIN MANAGEMENT SYSTEMS whitepaper the nasally administered systemic drugs market has an increasing generics sector, is placing greater emphasis on patient compliance and convenience, and is benefitting from an increasingly ageing population.In contrast, severe pressure on health care... Read More |
![Flexible Drug Containers for Parenteral Drugs]() FLEXIBLE DRUG CONTAINERS FOR PARENTERAL DRUGS whitepaper Valuable time of healthcare personnel, as well as high cost for time spent in hospitals, is outweighing the actual cost of drugs by far, thus increasing the total cost of treatment dramatically. Two thirds of injectable drugs are infused via infusion... Read More |
![The EU5 Market Access Landspace for Oncology Drugs]() THE EU5 MARKET ACCESS LANDSPACE FOR ONCOLOGY DRUGS whitepaper Global sales of oncology medicines were widely reported to
have exceeded $100 billion for the first time in 2014, with the
U.S. and European markets generating the majority of sales.
This trajectory is expected to continue: Decision Resources
Gro... Read More |
| |
| |
![Pharma is attracted to antibody deals in Oncology]() PHARMA IS ATTRACTED TO ANTIBODY DEALS IN ONCOLOGY whitepaper Antibody therapeutics clearly offer clinical benefi ts over
cheaper, older and mainly generic cytotoxic drugs. However,
due to their high development and manufacturing costs
and the cost to payers, they tend to get used as later-stage
treatments ... Read More |
![Bringing a new drug to life Regulatory Sciences]() BRINGING A NEW DRUG TO LIFE REGULATORY SCIENCES whitepaper For patients with severe neuropsychiatric conditions, the right drug was available—but there was a problem. The drug was in hard-tablet form, which often caused an issue with patient adherence. Patients would “cheek the pill,” instead of actually swa... Read More |
![CRISPR Delivery Challenges and Applications within Pharma]() CRISPR DELIVERY CHALLENGES AND APPLICATIONS WITHIN PHARMA whitepaper CRISPR is now one of the most affordable forms of gene editing causing a boom in R&D over the last few years.
However, the technique does have its limitations which include maintaining end to end control on geneti manipulation, avoiding off targets ... Read More |
| |
| |
![Defining Drug Response for Stratified Medicine]() DEFINING DRUG RESPONSE FOR STRATIFIED MEDICINE whitepaper The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. Howev... Read More |
| |
| |
| |
![Cleaning Validation for Pharmaceutical Manufacturing]() CLEANING VALIDATION FOR PHARMACEUTICAL MANUFACTURING whitepaper Cleaning validation is a necessary and time-consuming part of manufacturing pharmaceuticals. The validation process can be expedited and the cost reduced if the cleaner supplier can provide support — ultimately allowing pharmaceuticals to get to mark... Read More |
![Big Pharma Deal Making – The Beginning of a New Dawn?]() BIG PHARMA DEAL MAKING – THE BEGINNING OF A NEW DAWN? whitepaper It’s useful to review deal trends periodically to gain insight in how behaviours are changing from the perspective of numbers and value of deals as well as how emphasis shifts from one therapeutic area to another. The majority of small and mid-size d... Read More |
![Bugs as Drugs, Microbiome Dealmaking Poised to Take Off]() BUGS AS DRUGS, MICROBIOME DEALMAKING POISED TO TAKE OFF whitepaper Probiotics, prebiotics, medical food and supplements have been
commercially available as OTC products for some time. These products claim to support human health by restoring the balance of the gut microfl ora in favour of ‘benefi cial’ bacteria, mo... Read More |
| |
![Guide to Pharmaceutical Labelling Excellence]() GUIDE TO PHARMACEUTICAL LABELLING EXCELLENCE whitepaper The future of every pharmaceutical company is dependent on its efforts to find new ways to increase revenue, reduce costs, and reduce the risk of catastrophic product recalls. Labeling,
artwork management, and packaging are not usually considered pa... Read More |
![IC – The all-rounder in pharmaceutical analysis]() IC – THE ALL-ROUNDER IN PHARMACEUTICAL ANALYSIS whitepaper High standards have to be met by the pharmaceutical industry when it comes to drug quality and safety. These standards are documented in pharmacopoeias as officially recognised pharmaceutical rules, and published as legal tools of customer protection... Read More |
![Simple steps to speed encapsulated drug development]() SIMPLE STEPS TO SPEED ENCAPSULATED DRUG DEVELOPMENT whitepaper In the pharmaceutical industry, speed to market is essential for gaining a competitive position. New encapsulation technologies now make it possible to streamline research and development activities, improve product development, and jump-start time t... Read More |
![The Integrated Pharmaceutical Development Platform]() THE INTEGRATED PHARMACEUTICAL DEVELOPMENT PLATFORM whitepaper Despite breaking global sales records in 2015, biopharmaceutical companies are witnessing a slowing in growth and are under increasing pressure from payers and competitors to reduce costs1 Compounding this, a recent study has found that the average c... Read More |
|